Stay updated with breaking news from Patrickr Oneil. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) has been given a consensus recommendation of “Hold” by the fourteen ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. […]
M28 Capital Management LP bought a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 126,300 shares of the company’s stock, valued at approximately $4,770,000. Ionis Pharmaceuticals makes up 4.5% of M28 Capital Management LP’s holdings, making the stock its 6th largest […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) EVP Patrick R. O’neil sold 1,527 shares of the company’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $41.70, for a total transaction of $63,675.90. Following the sale, the executive vice president now directly owns 40,355 shares in the […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) – Stock analysts at Zacks Research increased their Q1 2023 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 19th. Zacks Research analyst K. Shah now forecasts that the company will earn ($1.00) per share […]
Sumitomo Mitsui Trust Holdings Inc. decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 23.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 336,732 shares of the company’s stock after selling 100,444 shares during the period. Sumitomo Mitsui […]